The FDA cleared Arrowhead Pharmaceuticals’ RNA interference therapy Redemplo (plozasiran) for familial chylomicronemia syndrome, marking the company’s first commercial product and the second RNAi therapy approved for the condition. Arrowhead highlighted safety and dosing attributes and announced a launch price materially below its competitor’s offering, setting up immediate commercial rivalry with Ionis Pharmaceuticals. Arrowhead’s Redemplo approval transitions the company into a commercial-stage biopharma and establishes a direct product-market test against Ionis’ therapy. The lower price point aims to accelerate uptake but also signals intensified price competition in rare-disease RNAi launches. Payers and clinicians will now evaluate comparative efficacy, dosing convenience, and cost when choosing between agents. The approval and pricing move are likely to reshape market dynamics in this rare lipid disorder and may influence how RNAi entrants position value versus incumbent oligonucleotide therapies.